Speedwell Bio

Our main goal is to develop customized fit-for-purpose assays that best serve a wide range of client needs in molecular biology. The team consists of a blend of experts with both academic and industry experience. Our company started in 2020 with funding from the CARES Act to develop a one-step RT-PCR assay for COVID testing in low resource/Point-of-Care environments. This work led us to develop relationships with diagnostic experts equipped with CLIA labs and the ability to carry out clinical validation of our assays. In parallel, we have also developed a wide range of oncology assays and have formed strong partnerships with labs at both UNC-Chapel Hill and Duke where we have ongoing collaborative projects in both oncology drug discovery and basic research. Our company is nimble and can switch priorities quickly at client’s request while maintaining low costs.